COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
ABX464 for COVID-19
Phase 2b/3 study of ABX464 in COVID-19 patients (miR-AGE)
Results from the miR-AGE study expected by year-end
DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury
Phase 2 study of DUR-928 in hospitalized COVID-19 infected patients with acute liver or kidney injury
Proteostasis Therapeutics, Inc.
PTI-129 as a treatment for COVID-19
PTC Therapeutics Inc.
PTC299 for the treatment for COVID-19
FDA has authorized initiation of a Phase 2/3 trial of PTC299
Lenzilumab in Severe and Critical COVID-19 Patients
Phase III trial of Lenzilumab in severe and critical COVID-19 patients
Citius Pharmaceuticals, Inc.
iMSC therapy to treat ARDS in COVID-19 patients
Submit an IND application for iMSC therapy for patients with Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Ford plans to bring back the Bronco as a dedicated off-road brand when it launches an all-new 4x4 SUV lineup on July 13. The automaker said it will introduce an all-new Bronco brand under the tagline, "Built Wild". The new lineup includes two-door and four-door models of the Bronco as well as the Bronco Sport compact SUV. J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles.